Profitability ratios measure the company ability to generate profitable sales from its resources (assets).
Paying user area
Try for free
Bristol-Myers Squibb Co. pages available for free this week:
- Common-Size Balance Sheet: Assets
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Liquidity Ratios
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Analysis of Geographic Areas
- Enterprise Value to EBITDA (EV/EBITDA)
- Capital Asset Pricing Model (CAPM)
- Total Asset Turnover since 2005
- Price to Sales (P/S) since 2005
- Aggregate Accruals
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Bristol-Myers Squibb Co. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Profitability Ratios (Summary)
Based on: 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).
The quarterly financial data reveals notable fluctuations in profitability and efficiency metrics over the analyzed periods.
- Gross Profit Margin
-
The gross profit margin displayed a generally upward trend early in the timeline, increasing from approximately 74.42% to a peak above 79.6% between early 2021 and early 2022. Following this peak, there is a gradual decline through to early 2025, where the margin trends down to around 69.5%. This suggests a decreasing efficiency in production or higher cost of goods sold relative to revenue over the later periods.
- Operating Profit Margin
-
Operating profit margins present a pattern of significant volatility. Initially, negative margins were observed, improving from -19.19% to near positive territory by the end of 2021. From early 2022 through late 2023, margins remained strongly positive, peaking around 19%. However, notable declines occur thereafter, with margins dropping to roughly -14% in early 2024 before recovering again towards positive values exceeding 18% by late 2025. This fluctuation indicates periods of operational difficulty interspersed with recoveries, possibly linked to varying operational costs or revenue changes.
- Net Profit Margin
-
Net profit margin trends mirror those of operating profit margin to some extent, moving from negative values toward positive margins starting in late 2021. Margins peaked around 18.4% in late 2023 but experienced a substantial drop into negative figures near early 2024, before rebounding towards positive margins above 12% by late 2025. This variability reflects net income sensitivity to not only operational performance but also other financial factors such as taxes, interest, or extraordinary items.
- Return on Equity (ROE)
-
ROE shows significant swings, moving from strong negatives in early 2021 to peak positive returns exceeding 28% by late 2023. This improvement suggests enhanced shareholder value generation during that period. Nevertheless, a drastic decline occurs with steep negative returns through 2024, reaching nearly -55% at one point. The ROE then recovers impressively to above 32% by late 2025. These drastic changes indicate substantial shifts in net income relative to equity, possibly due to extraordinary losses or gains, equity base changes, or other impairments.
- Return on Assets (ROA)
-
ROA also mirrors the pattern seen in ROE but with less extreme magnitudes. Negative returns early on give way to modest positive returns just above 9% by late 2023, followed by a drop back into negative territory during 2024, before climbing again to around 6% by late 2025. This implies fluctuations in the company's asset utilization efficiency, influenced by operational results and asset base changes.
Overall, the financial ratios indicate a cycle of recovery and setback, with a strong performance period between late 2021 and late 2023, followed by a pronounced decline in 2024 and subsequent recovery into 2025. The recurring sharp declines may suggest episodic challenges impacting earnings and returns. The downward trend in gross profit margin towards the end of the timeline indicates potential margin pressures that should be monitored.
Return on Sales
Return on Investment
Gross Profit Margin
| Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||
| Gross margin | |||||||||||||||||||||||||
| Revenues | |||||||||||||||||||||||||
| Profitability Ratio | |||||||||||||||||||||||||
| Gross profit margin1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| Gross Profit Margin, Competitors2 | |||||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).
1 Q3 2025 Calculation
Gross profit margin = 100
× (Gross marginQ3 2025
+ Gross marginQ2 2025
+ Gross marginQ1 2025
+ Gross marginQ4 2024)
÷ (RevenuesQ3 2025
+ RevenuesQ2 2025
+ RevenuesQ1 2025
+ RevenuesQ4 2024)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
- Gross Margin Analysis
- The gross margin values exhibit a fluctuating pattern over the observed periods. Initially, there is a rising trend from March 2021 through December 2021, with margins increasing from 8,232 million to 9,629 million US dollars. Subsequently, a gradual decline is observed through 2022 and 2023, with figures decreasing to a low around 7,530 million by December 2024. There is some recovery and volatility in 2024 and early 2025, with gross margins rising back near 8,900 million before slightly declining again by September 2025. Overall, the gross margin trend suggests periods of growth followed by contraction and moderate recovery, indicating variability in cost management or sales mix.
- Revenue Trends
- Revenue figures show some variability but with less pronounced fluctuation compared to gross margins. Revenues rise from 11,073 million in March 2021 to a peak of 12,342 million in December 2024, indicating steady growth over the medium term. However, there are intermittent decreases in revenue, notably in late 2022 and mid-to-late 2025, where revenue dips to approximately 11,201 million. This pattern suggests generally positive sales performance with occasional setbacks, potentially due to market or operational factors affecting certain quarters.
- Gross Profit Margin Percentage
- The gross profit margin percentage shows a consistent downward trend over the full period. Starting from 74.42% in March 2021, it increases slightly to a peak near 79.62% in early 2022, then steadily declines through 2023 and 2024, reaching approximately 69.5% by September 2025. This decline indicates rising costs of goods sold relative to revenues or decreasing pricing power, which negatively impacts profitability at the gross level. The sustained decrease in gross profit margin percentage despite fluctuations in gross margin dollars and revenues may point to increased cost pressures or changing product/service mix over time.
- Overall Insights
- The financial data reveals a company experiencing growth in revenues over the analyzed quarters, yet facing challenges in maintaining or improving gross margin both in absolute and percentage terms. The diminishing gross profit margin percentage signals a need to address cost efficiency or pricing strategies to sustain profitability. The fluctuations and periodic declines in gross margin indicate possible operational or market dynamics influencing cost control. The relatively steadier revenue pattern suggests a stable demand environment, although some quarters reflect softness that could merit further examination. Collectively, the trends highlight areas for potential improvement in cost management and margin optimization to enhance financial performance moving forward.
Operating Profit Margin
| Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||
| Operating income (loss) | |||||||||||||||||||||||||
| Revenues | |||||||||||||||||||||||||
| Profitability Ratio | |||||||||||||||||||||||||
| Operating profit margin1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| Operating Profit Margin, Competitors2 | |||||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).
1 Q3 2025 Calculation
Operating profit margin = 100
× (Operating income (loss)Q3 2025
+ Operating income (loss)Q2 2025
+ Operating income (loss)Q1 2025
+ Operating income (loss)Q4 2024)
÷ (RevenuesQ3 2025
+ RevenuesQ2 2025
+ RevenuesQ1 2025
+ RevenuesQ4 2024)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
- Operating Income (Loss)
- The operating income demonstrates volatility over the observed periods. Initially, it exhibits a generally positive trend from 1828 million USD in March 2021, peaking at 2357 million USD in March 2023. However, a significant decline to a negative value of -11435 million USD is observed in March 2024, followed by recovery in the subsequent quarters, fluctuating between 480 million USD and 3309 million USD. This sharp loss in early 2024 indicates an extraordinary event or write-down impacting operating results substantially. Post this event, operating income shows a recovery trend but remains unstable.
- Revenues
- Revenues maintain a relatively stable pattern throughout the periods, fluctuating within a narrow range generally between approximately 10,900 million USD and 12,300 million USD. There is no clear upward or downward long-term trend, though minor cyclical variations are present. Notably, revenue holds steady even during the period of significant operating losses in early 2024, suggesting operating losses were not driven by top-line decline but potentially increased costs or exceptional charges.
- Operating Profit Margin
- The operating profit margin aligns with the operating income trends, exhibiting considerable fluctuations. It begins with negative values in the initial quarters of 2021, quickly transitioning into positive territory around the end of 2021 and maintaining positive margins through early 2023. A marked decline occurs in March and June 2024, with margins falling sharply negative (around -14%), coinciding with the operating loss event. Following this, margins recover, returning to positive percentages ranging from approximately 15% to 19%, indicating restoration of profitability after the downturn.
- Summary of Trends
- The data reveals a company experiencing stable revenue generation but facing significant variations in profitability. The sharp loss in early 2024 is a notable anomaly, heavily impacting operating income and margins. This event appears isolated from revenue performance, implying that operational challenges or extraordinary factors severely affected earnings. Recovery after this period is evident, with margins and operating income rebounding moderately but continuing to demonstrate volatility. Overall, the financial performance suggests resilience in sales but highlights risks related to cost management or non-recurring items that affect operating results.
Net Profit Margin
| Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||
| Net earnings (loss) attributable to BMS | |||||||||||||||||||||||||
| Revenues | |||||||||||||||||||||||||
| Profitability Ratio | |||||||||||||||||||||||||
| Net profit margin1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| Net Profit Margin, Competitors2 | |||||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).
1 Q3 2025 Calculation
Net profit margin = 100
× (Net earnings (loss) attributable to BMSQ3 2025
+ Net earnings (loss) attributable to BMSQ2 2025
+ Net earnings (loss) attributable to BMSQ1 2025
+ Net earnings (loss) attributable to BMSQ4 2024)
÷ (RevenuesQ3 2025
+ RevenuesQ2 2025
+ RevenuesQ1 2025
+ RevenuesQ4 2024)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
- Net Earnings (Loss) Attributable to BMS
- The net earnings exhibit notable volatility throughout the observed periods. Initially, there is a rising trend from 2021 into late 2022, peaking at 2,262 million USD by December 31, 2021, and again reaching high points near 2,022 million USD by December 31, 2022. However, a substantial decline occurs around the first quarter of 2024, with a significant loss reported at -11,911 million USD. Following this sharp downturn, the company recovers somewhat, but earnings remain irregular with a lower magnitude of profits and occasional dips, signaling instability in profitability towards the end of the period.
- Revenues
- Revenue figures demonstrate relative stability with modest fluctuations across the quarters. The revenues range mostly between approximately 11,000 million USD to 12,300 million USD, peaking in mid-2024 at 12,342 million USD. Overall, there is no clear upward or downward long-term trend, indicating that the company maintains a consistent revenue base despite fluctuations in net earnings.
- Net Profit Margin
- The net profit margin displays variability connected to the swings in net earnings. Initially, margins are negative or low positive percentages, reflecting some instability in profitability. From late 2021 through 2023, profit margins generally hold positive values mostly ranging from around 13% to 18%, demonstrating periods of relatively strong profitability. However, in 2024, coinciding with the large net loss, margins drop sharply into negative territory again, going as low as -18.53%. Margins rebound back into positive territory toward 2025 with moderate percentages around 10-12%, indicating some normalization but with lower profitability than earlier positive periods.
- Summary of Trends
- Overall, the data reveal that while the company maintains stable revenues, its profitability exhibits significant volatility. A pronounced loss in early 2024 severely impacts net earnings and profit margins, interrupting a previously more stable and profitable pattern. Recovery attempts are visible in subsequent quarters but do not fully reach earlier peak profitability levels. This suggests that underlying challenges or extraordinary events affected financial performance during the 2024 period, with ongoing efforts to restore financial health thereafter.
Return on Equity (ROE)
| Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||
| Net earnings (loss) attributable to BMS | |||||||||||||||||||||||||
| Total BMS shareholders’ equity | |||||||||||||||||||||||||
| Profitability Ratio | |||||||||||||||||||||||||
| ROE1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| ROE, Competitors2 | |||||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).
1 Q3 2025 Calculation
ROE = 100
× (Net earnings (loss) attributable to BMSQ3 2025
+ Net earnings (loss) attributable to BMSQ2 2025
+ Net earnings (loss) attributable to BMSQ1 2025
+ Net earnings (loss) attributable to BMSQ4 2024)
÷ Total BMS shareholders’ equity
= 100 × ( + + + )
÷ =
2 Click competitor name to see calculations.
The financial performance over the presented periods exhibits notable fluctuations, particularly in net earnings and return on equity (ROE), while shareholder equity demonstrates relative stability with a declining trend in the middle periods followed by modest recovery.
- Net Earnings (Loss) Attributable to BMS
- The net earnings showed a general increase from early 2021 through 2023, reaching peaks in the last quarters of 2021 and 2022. Notably, the value declined sharply to a significant loss in the first quarter of 2024, which is an outlier compared to other periods. Following this loss, earnings gradually recovered but did not exceed previous peak levels by the end of 2025.
- Total BMS Shareholders’ Equity
- Equity levels began around $37.6 billion in early 2021, experienced a gradual decline through 2022 and early 2023, reaching a low in late 2023 to early 2024 near $16.5 billion. This drop indicates significant financial strain or substantial adjustments during that time frame. Subsequently, equity levels showed slight recovery and stabilization toward the end of 2025, reaching approximately $18.5 billion.
- Return on Equity (ROE)
- ROE percentages demonstrated positive returns throughout most periods of 2021 to 2023, with a gradual upward trend that peaked near 28-29%. The first quarter of 2024 marked a severe negative return, corresponding with the significant net loss and equity decline observed. The ROE remained deeply negative in the initial three quarters of 2024, indicating poor profitability relative to equity during that time. Recovery in profitability is evident from the end of 2024 onward, with ROE values rebounding sharply to above 30% by 2025.
Overall, the data reveal significant volatility with a pronounced disruption in early 2024 characterized by large net losses, depleted equity, and negative profitability. Despite these setbacks, the company shows signs of financial recovery with improving earnings, equity, and ROE toward the end of the observed period.
Return on Assets (ROA)
| Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||
| Net earnings (loss) attributable to BMS | |||||||||||||||||||||||||
| Total assets | |||||||||||||||||||||||||
| Profitability Ratio | |||||||||||||||||||||||||
| ROA1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| ROA, Competitors2 | |||||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).
1 Q3 2025 Calculation
ROA = 100
× (Net earnings (loss) attributable to BMSQ3 2025
+ Net earnings (loss) attributable to BMSQ2 2025
+ Net earnings (loss) attributable to BMSQ1 2025
+ Net earnings (loss) attributable to BMSQ4 2024)
÷ Total assets
= 100 × ( + + + )
÷ =
2 Click competitor name to see calculations.
The quarterly financial data reveals multiple fluctuations and trends in key performance indicators over the observed periods.
- Net Earnings (Loss) Attributable to BMS
- The net earnings show significant variability across quarters. Initial quarters display generally positive earnings, with a notable increase reaching a peak around the last quarter of 2021. However, an abrupt and substantial negative value appears in the first quarter of 2024, indicating a significant loss. Following this loss, the net earnings return to positive but exhibit lower and fluctuating figures without a clear upward trend through the subsequent quarters.
- Total Assets
- Total assets show a gradual declining trend from the beginning of the period through the end of 2023, indicating a contraction in the asset base. However, starting at the end of 2023 and into 2024 and 2025, total assets begin to show a recovery with steady increases, suggesting either asset acquisitions or improved asset management in the most recent periods.
- Return on Assets (ROA)
- ROA values demonstrate volatility with alternating positive and negative returns. Initially, ROA is negative but improves to positive levels during 2021 and sustains mostly positive performance until the end of 2023. In 2024, ROA deteriorates sharply into negative territory coinciding with the period of notable net loss. Toward the end of the dataset, ROA recovers into positive territory once again, emphasizing a rebound in asset profitability.
Overall, the data indicates a period of financial instability marked by significant earnings fluctuations and periods of asset decline, especially around 2023-2024. The recovery in total assets and ROA towards 2025 suggests a return to more stable financial conditions following the challenges indicated by the large loss and negative returns in early 2024.